S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:BCEL

Atreca (BCEL) Stock Forecast, Price & News

$0.28
-0.04 (-12.50%)
(As of 09/25/2023 ET)
Compare
Today's Range
$0.28
$0.31
50-Day Range
$0.28
$1.12
52-Week Range
$0.28
$2.05
Volume
266,509 shs
Average Volume
126,765 shs
Market Capitalization
$11.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75

Atreca MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
3,739.3% Upside
$10.75 Price Target
Short Interest
Bearish
9.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$9,085 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.73) to ($0.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

504th out of 961 stocks

Pharmaceutical Preparations Industry

229th out of 454 stocks


BCEL stock logo

About Atreca (NASDAQ:BCEL) Stock

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

BCEL Price History

BCEL Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Stifel Downgrades Atreca Inc - (BCEL)
Stifel Nicolaus Reaffirms Their Buy Rating on Atreca (BCEL)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Atreca (BCEL) Gets a Buy from H.C. Wainwright
Atreca (NASDAQ: BCEL)
Stifel Nicolaus Sticks to Their Buy Rating for Atreca (BCEL)
Atreca (BCEL) Earnings Dates & Reports
See More Headlines
Receive BCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter.

BCEL Company Calendar

Last Earnings
8/10/2023
Today
9/26/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCEL
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.75
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+3,739.3%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-97,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.01 per share

Miscellaneous

Free Float
34,856,000
Market Cap
$11.00 million
Optionable
Not Optionable
Beta
1.17
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. John A. Orwin M.B.A. (Age 58)
    Pres, CEO & Director
    Comp: $927.03k
  • Dr. Tito A. Serafini Ph.D. (Age 60)
    Founder, Chief Strategy Officer & Director
    Comp: $665.5k
  • Dr. Stephen E. Gould Ph.D. (Age 58)
    Chief Scientific Officer
    Comp: $380.52k
  • Mr. Herbert C. Cross (Age 51)
    Chief Financial Officer
  • Ms. Courtney J. Phillips J.D. (Age 48)
    Gen. Counsel & Corp. Sec.
  • Dr. Philippe C. Bishop M.D. (Age 58)
    Chief Medical Officer













BCEL Stock - Frequently Asked Questions

Should I buy or sell Atreca stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares.
View BCEL analyst ratings
or view top-rated stocks.

What is Atreca's stock price forecast for 2023?

5 brokerages have issued 1-year price objectives for Atreca's stock. Their BCEL share price forecasts range from $4.00 to $25.00. On average, they predict the company's share price to reach $10.75 in the next year. This suggests a possible upside of 3,739.3% from the stock's current price.
View analysts price targets for BCEL
or view top-rated stocks among Wall Street analysts.

How have BCEL shares performed in 2023?

Atreca's stock was trading at $0.8006 on January 1st, 2023. Since then, BCEL stock has decreased by 65.0% and is now trading at $0.28.
View the best growth stocks for 2023 here
.

When is Atreca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BCEL earnings forecast
.

How were Atreca's earnings last quarter?

Atreca, Inc. (NASDAQ:BCEL) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.07.

What is John Orwin's approval rating as Atreca's CEO?

6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend.

What other stocks do shareholders of Atreca own?
When did Atreca IPO?

(BCEL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

What is Atreca's stock symbol?

Atreca trades on the NASDAQ under the ticker symbol "BCEL."

Who are Atreca's major shareholders?

Atreca's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.04%), Bill & Melinda Gates Foundation (2.38%), ExodusPoint Capital Management LP (1.19%), CM Management LLC (0.89%), Renaissance Technologies LLC (0.81%) and Acadian Asset Management LLC (0.11%). Insiders that own company stock include John A Orwin, Norman Michael Greenberg, Phillips Courtney, Tito Serafini and William Hewitt Robinson.
View institutional ownership trends
.

How do I buy shares of Atreca?

Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atreca's stock price today?

One share of BCEL stock can currently be purchased for approximately $0.28.

How much money does Atreca make?

Atreca (NASDAQ:BCEL) has a market capitalization of $11.00 million. The company earns $-97,160,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.

How can I contact Atreca?

Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The official website for the company is www.atreca.com. The company can be reached via phone at (650) 595-2595 or via email at ir@atreca.com.

This page (NASDAQ:BCEL) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -